Metsera (NASDAQ:MTSR) Reaches New 1-Year Low – Should You Sell?

Metsera, Inc. (NASDAQ:MTSR)’s stock price hit a new 52-week low during trading on Tuesday . The stock traded as low as $15.34 and last traded at $16.45, with a volume of 1606066 shares changing hands. The stock had previously closed at $16.80.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on MTSR shares. Cantor Fitzgerald initiated coverage on Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating for the company. Bank of America started coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $38.00 price target for the company. Guggenheim assumed coverage on shares of Metsera in a report on Tuesday, February 25th. They set a “buy” rating and a $56.00 target price for the company. Finally, Evercore ISI began coverage on Metsera in a research note on Tuesday, February 25th. They set an “outperform” rating for the company.

Metsera Stock Up 7.5 %

The company’s fifty day moving average price is $26.28.

Metsera (NASDAQ:MTSR) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($3.52) EPS for the quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.